期刊文献+

PI3K/Akt信号通路调节红系细胞生成的研究进展 被引量:3

下载PDF
导出
摘要 磷脂酰肌醇3-激酶(phosphoinositide 3-kinase,PI3K)家族是一类特异性催化磷酯酰肌醇脂物质的激酶,具有丝氨酸/苏氨酸激酶的活性,也具有磷脂酞肌醇激酶的活性,广泛存在于细胞中,通过激素受体、跨膜酪氨酸激酶受体和各种细胞因子应答各种细胞内、外信息,并调控细胞生长、增殖、分化、凋亡等。
作者 赵成玉 崔森
出处 《实用医学杂志》 CAS 北大核心 2016年第6期1019-1021,共3页 The Journal of Practical Medicine
基金 国家自然科学基金项目(编号:81260300) 青海省科技创新能力促进计划项目(编号:2014-ZJ-922)
  • 相关文献

参考文献24

  • 1董自强,江克华,宋兴福,陈先国,陈晓波,袁红纲,刘幼昆,龙兵.抑制PI3K/Akt信号通路提高膀胱癌化疗效果的实验研究[J].实用医学杂志,2012,28(2):181-183. 被引量:7
  • 2KIM WS, ZHU Y, DENG Q,et al. Erythropoiesis from humanembryonic stem cells through erythropoietin-independent AKTsignaling [J]. Stem Cells, 2014,32(6) : 1503-1514.
  • 3WANG J, RAMIREZ T,JI P,et al. Mammalian erythroblastenucleation requires PI3K-dependent cell polarization [J]. JCell Sci, 2012,125(Pt 2) :340-349.
  • 4SLAVOVA-AZMANOVA NS, KUCERA N, LOUWA,et al.Lyn kinase plays important roles in erythroid expansion,maturation and erythropoietin receptor signalling by regulatinginhibitory signalling pathways that control survival [J]. BiochemJ, 2014,459(3):455-466.
  • 5UANG R, CAMPRECIOS G, KOU Y, et al. A systemsapproach identifies essential F0X03 functions at key steps ofterminal erythropoiesis [J]. PLoS Genet, 2015,11( 10):el005526.
  • 6WANG H,LI Y,WANG S, et al. Knockdown of transcriptionfactor forkhead box 03 (F0X03) suppresses erythroiddifferentiation in human cells and zebrafish [J], BiochemBiophys Res Commun, 2015,460(4) :923-930.
  • 7ZHANG X,CAMPRECIOS G, RIMMELE P, et al. F0X03-mTOR metabolic cooperation in the regulation of erythroid cellmaturation and homeostasis [J]. Am J Hematol, 2014,89(10):954-963.
  • 8FRANCO SS,DE FALCO L, GHAFFARI S, et al. Resveratrolaccelerates erythroid maturation by activation of Fox03 andameliorates anemia in beta-thalassemic mice [J]. Haematologica,2014,99(2):267-275.
  • 9SPITALIP,GRUMATI P, HILLER M, et al. Autophagy isimpaired in the tibialis anterior of dystrophin null mice [J].PLoS Curr, 2013,5( 1) : 1-13.
  • 10AN X. Exosome complex and erythropoiesis [J]. Blood, 2014,124(14):2169-2171.

二级参考文献8

  • 1Carnero A. The PKB/AKT Pathway in Cancer[J]. Curr Pharm Des, 2010,16( 1 ) : 34-44.
  • 2Dell'Eva R, Ambrosini C, Minghelli S, et al. The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-kappaB pathway [J]. Carcinogenesis, 2007,28 (2): 404-413.
  • 3Jemal A, Siegel R, Xu J, et al. Cancer Statistics, 2010[J]. CA Cancer J Clin, 2010,60(5) :277-300.
  • 4Clark A S, West K, Streicher S, et al. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells[J]. Mol Cancer Ther, 2002,1 (9) : 707-717.
  • 5Warshamana-Greene G S, Litz J, Buchdunger E, et al. The insulin-like growth factor-I receptor kinase inhibitor, NVP- ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy [J]. Clin Cancer Res, 2005,11(4): 1563-1571.
  • 6Evanqelisti C, Ricei F, Tazzari P,et al. Preelinieal testing of the Akt inhibitor triciribine in T-cell acute lymphoblastie leukemia [J]. J Cell Phvsiol. 2011. 226 ( 3 ) : 822-831.
  • 7Yap T A, Walton M I, Hunter L J, pharmacology, antitumor activity, pharmacodynamic markers for the novel, CCT128930 [J]. Mol Cancer Ther, 2011 et al. Preclinical and development of potent AKT inhibitor 10(2) :360-371.
  • 8Hirai H, Sootome H, Nakatsuru Y, et al. MK-2206, allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo [J]. Mol Cancer Ther, 2010,9(7):1956- 1967.

共引文献6

同被引文献17

引证文献3

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部